血清表皮生长因子与肺癌关系的研究

采用放射免疫法检测36例肺癌、30例肺良性疾病和30例健康体检查血清EGF水平,结果表明：肺癌患血清EGF水平显高于显高于肺良性疾病组和健康对照组（P＜0．01）,肺癌伴癌转移比未转移血清GEF更高（P＜0．05）,肺癌化疗后血清EGF水平明显下降（P＜0．05）。 检测血清EGF水平可以作为肺癌诊断,估计病情,判断化疗效果的一种生物指标。     

胃肠道肿瘤血清表皮生长因子水平分析

表皮生长因子（Ｅｐｉｄｅｒｍａｌｇｒｏｗｔｈｆａｃｔｏｒ,ＥＧＦ）是由颌下腺、Ｂｒｕｎｎｅｒ腺以及大肠潘氏细胞分泌的一种胃肠激素。近年来ＥＧＦ在肿瘤发生和发展中的作用日益受到重视,认为ＥＧＦ与癌基因的表达有关。目前,关于胃肠道肿瘤ＥＧＦ受体研究较多,...     

肺癌患者手术前后血清表皮生长因子水平的变化

肺癌患者手术前后血清表皮生长因子水平的变化兰州军区总医院（兰州市７３００５０）刘杜姣李焕章李乃斌马晓惠近年来对生长因子尤其是表皮生长因子族、癌基因、生长因子受体以及抑癌基因的研究十分活跃。实验证明表皮生长因子（ＥＧＦ）能刺激多个瘤细胞株的生长，当Ｅ...     

表皮生长因子受体单克隆抗体抗肺癌作用的研究

目的 实验观察表皮生长因子受体单克隆抗体（ＥＧＦＲ ＭcＡb）egf／r３对肺癌的治疗 作用。方法 体外细胞增殖抑制实验采用ＭＴＴ法,裸鼠体内移植瘤采用同时治疗（Ｔ１组）与一治疗（Ｔ２组）两种方案。结果 egf／r３ＭcＡb对高表达ＥＧＦＲ的ＳＰＣ－Ａ１和Ａ５４９肺癌细胞体外均具有增殖抑制作用,并呈剂量依赖性;以ＳＰＣ－Ａ１进行裸鼠皮下移植体内实验,至治疗结束,Ｔ１组与５０％成瘤（３/６）,对照组１００％成瘤（     

肝癌组织中表皮生长因子含量的研究

用放免法定量检测肝癌组织，癌旁组织和正常肝组织中表皮生长因子（ＥＧＦ）含量。癌旁组织ＥＧＦ含量显著高于正常肝组织。癌组织与癌旁组织比较，其ＥＧＦ含量无显著性差异。作者认为ＥＧＦ对肝癌的发生发展有重要的促进作用，这种作用始于癌前病变     

表皮生长因子在肺癌治疗中的应用

表皮生长因子(EGF)及受体信号通路在非小细胞肺癌(NSCLC)的发生和发展中起重要作用.本文综述肺癌EGF及其受体(EGFR)的一般特性、作用机制、生物学功能、酪氨酸激酶拮抗剂(TKI)在肺癌靶向治疗中的作用以及EGF肿瘤疫苗治疗NSCLC的价值.     

雌激素及其受体与表皮生长因子受体突变肺癌的关系

肺癌是全球发病率和病死率最高的恶性肿瘤,男性和女性肺癌患者的临床特征各不相同。越来越多证据表明雌激素及其受体参与了肺癌的发生和发展过程,其中的机制包括雌激素受体(ER)通路与表皮生长因子受体(EGFR)通路相互作用,且肺癌组织的ER表达水平可能与表皮生长因子受体酪氨酸激酶抑制剂(EGFRTKI)的疗效相关,抗雌激素药物联合EGFR-TKI表现出良好的抗肿瘤作用。本文就雌激素及其受体与EGFR突变肺癌的关系、抗雌激素药物联合EGFR-TKI在肺癌的应用作一综述。     

肝癌组织中表皮生长因子含量的研究

用放免法定量检测肝癌组织，癌旁组织和正常肝组织中表皮生长因子（EGF）含量。癌旁组织EGF含量显著高于正常肝组织。癌组织与癌旁组织比较，其EGF含量无显著性差异。作者认为EGF对肝癌的发生发展有重要的促进作用，这种作用始于癌前病变。     

胃癌患者血清表皮生长因子测定的临床评价

目的　探讨胃癌患者血清表皮生长因子 (EGF)水平变化的临床价值。方法　采用放射免疫分析 (RIA)对46例胃癌患者进行测定EGF的含量。结果　胃癌患者血清EGF水平显著高于正常对照组 (P <0 .0 1)且中晚期胃癌组亦显著高于早期胃癌组 (P <0 .0 5 )。结论　胃癌患者检测EGF水平有助于判断胃癌的恶性程度及预后评价。     

表皮生长因子及其受体与肝癌的关系

EGF、EGFR具有广泛的生理作用，体内分布广泛，在肝癌的形成、复发及转移过程中，EGF、EGFR与Ca^2 通道、Na^ -H^ 通道、磷脂酰肌醇信息传递通道、基因表达异常、肿瘤血管及间质的形成关系密切，提示了治疗肝癌的新方向。现就EGF、EGFR与肝癌的形成、转移、复发的关系及其在临床中的应用前景作一综述。     

Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors

Interstitial lung disease (ILD) refers to a diverse range of pulmonary fibrotic disorders and may be hard to accurately diagnose, as distinguishing it from other pulmonary diseases can be difficult. Estimations of the incidence in populations are confounded by the complexity of the different forms of the disorder. In addition, ILD is a comorbid disease of lung cancer and is seen after most forms of chemotherapy and radiotherapy for advanced lung cancer. Incidences of >or=10% have been reported; however, whatever the true incidence, both chemotherapy and radiotherapy enhance the risk of developing ILD. ILD has also been reported with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, including erlotinib (Tarceva, OSI-774) and gefitinib (IRESSA). In a large number of gefitinib-treated patients (n > 185,000) an incidence of approx 1% has been observed (approx 2% in Japan; 0.3% in the rest of the world). Nevertheless, as with other treatments for advanced non-small-cell lung cancer, the clinical benefit outweighs the risk of ILD. In this article, we review the data on ILD with EGFR inhibitors and other common lung cancer treatments.     

Targeting epidermal growth factor receptor in lung cancer

Among the most promising agents in clinical development to treat non-small-cell lung cancer (NSCLC) are the epidermal growth factor receptor (EGFR) targeting agents. A series of recent studies have demonstrated the activity of anti-EGFR targeted therapies for NSCLC. In advanced NSCLC that is refractory to chemotherapy, antitumor responses have been reported with EGFR tyrosine kinase inhibitors (ZD1839 and OSI-774). The role of ZD1839 and OSI-774 as possible additions to standard chemotherapy in the first-line setting has also been evaluated, and the studies conducted to date should respond to the question of whether these compounds could provide a survival benefit. Other areas of research involve looking at the role of EGFR tyrosine kinase inhibitors in the neoadjuvant treatment of stage III NSCLC and the planning of chemoprevention studies. These exciting results and plans are further complemented by an emerging number of compounds in clinical development, including both monoclonal antibodies (ie, IMC-C225) and other tyrosine kinase inhibitors, directed at the EGFR.     

Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancer

Background: Using an enzyme immunoassay for epidermal growth factor receptor (EGFR), we investigated whether serum EGFR levels could be used as predictors of the development and extent of lung cancer. Methods: The study included 106 lung cancer patients and 16 patients with nonmalignant thoracic disease. Serum samples were collected before clinical treatment. Results: There was no difference between serum EGFR levels in patients with lung cancer (21.275 ± 22.035 fm/ml) in comparison with those in nonmalignant-disease controls (22.630 ± 7.330 fm/ml; P = 0.8083). However, lung cancer patients with lymph node metastasis (23.515 ± 20.065 fm/ml) had significantly higher EGFR levels compared with those in patients without lymph node metastasis (16.390 ± 10.970 fm/ml; P = 0.0228). The serum EGFR levels were similar in samples from lung cancer patients with various pathological subtypes. There was no difference in the prognosis between the lung cancer group with normal EGFR levels (<850 ng/ml) and the group with elevated EGFR levels (>850 ng/ml). Conclusion: Serum EGFR levels may serve as a marker that can be used as an indicator of lymph node metastasis in lung cancer. However, there was no difference between levels in patients with lung cancer and those in nonmalignant-disease controls, indicating that the measurement of serum EGFR levels was of limited value in the detection of lung cancer. Received: April 18, 2002 / Accepted: January 6, 2003 Correspondence to:H. Sasaki     

Image-guided thermal ablation for patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer

Nonsmall cell lung cancer (NSCLC) is treated by various therapies such as surgical intervention, radiotherapy, chemotherapy, molecular targeted therapy, and immunotherapy. Currently, molecular targeted therapy, including epidermal growth factor receptor (EGFR) inhibitors and Anaplastic Lymphoma Kinase (ALK) and Kirsten Rat Sarcoma viral Oncogene (KRAS) inhibitors, has received much attention and improved the prognosis of NSCLC. Nevertheless, the terminal point of molecular targeted drugs is resistance. Drug resistance has been classified into oligoprogression and extensive progression based on the tumor lesion progression after drug resistance. There is extensive research demonstrating that local therapy (surgical resection, radiotherapy, and thermal ablation) can prolong the survival of patients with drug resistance. This review is intended to determine the efficacy of image-guided thermal ablation in patients with NSCLC with EGFR mutation.     

Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib

A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. An enzyme-linked immunosorbent assay was used to determine levels of HGF in serum from 96 Japanese patients with advanced non-squamous NSCLC. The peptic nucleic acid-locked nucleic acid clamp method was used to determine their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response to gefitinib therapy and risk factors associated with prognosis. HGF-positive serum status (hazard ratio, 1.536; 95% confidence interval, 1.042-2.400; P = 0.0295) had a significant and independent negative effect on progression-free survival among patients with wild-type EGFR. We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR.     

Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.

PURPOSE: Epidermal growth factor (EGF) might be a suitable immunotherapeutic target in non-small-cell lung cancer (NSCLC). Our approach consists of active immunotherapy with EGF. The aim of the study is to characterize the humoral response and its effects on signal transduction in relation with the clinical outcome. EXPERIMENTAL DESIGN: Eighty NSCLC patients treated with first-line chemotherapy were randomized to receive the EGF vaccine or supportive care. EGF concentration in sera, anti-EGF antibodies and their capacity to inhibit the binding between EGF/EGF receptor (EGFR), and the EGFR phosphorylation were measured. RESULTS: Seventy-three percent of vaccinated patients developed a good antibody response, whereas none of the controls did. In good antibody-responder patients, self EGF in sera was significantly reduced. In 58% of vaccinated patients, the post-immune sera inhibited EGF/EGFR binding; in the control group, no inhibition occurred. Post-immune sera inhibited the EGFR phosphorylation whereas sera from control patients did not have this capacity. Good antibody-responder patients younger than 60 years had a significantly better survival. A high correlation between anti-EGF antibody titers, EGFR phosphorylation inhibition, and EGF/EGFR binding inhibition was found. There was a significantly better survival for vaccinated patients that showed the higher capacity to inhibit EGF/EGFR binding and for those who showed an immunodominance by the central region of EGF molecule. CONCLUSIONS: Immunization with the EGF vaccine induced neutralizing anti-EGF antibodies capable of inhibiting EGFR phosphorylation. There was a significant positive correlation between antibody titers, EGF/EGFR binding inhibition, immunodominance of anti-EGF antibodies, and survival in advanced NSCLC patients.     

肺癌表皮生长因子受体分子显像的研究进展*

表皮生长因子酪氨酸抑制剂是肺癌治疗中应用广泛的靶向药物,而其疗效的预测主要依靠有创的基因检测方法或粗略的临床估计。PET受体显像是集配体结合高特异性和放射性探测高敏感性于一体的显像技术。目前,以EGFR受体为靶点的PET显像研究正处于药物研发阶段,研究表明此种显像技术有助于建立肺癌靶向治疗疗效的无创性影像学检测,为肺癌的个体化治疗提供更多依据。      

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients

BACKGROUND: Clinical predictors including Asian, female, adenocarcinoma and never-smoker and epidermal growth factor mutation are associated with gefitinib responsiveness in non-small-cell lung cancer. Direct comparison between clinical predictors and EGFR mutation for their predictive power has not been reported. PATIENTS AND METHODS: For 120 Korean NSCLC patients treated with gefitinib, we have analyzed EGFR mutational status in exons 18, 19 and 21. Patients were grouped according to the number of clinical predictors (female, adenocarcinoma and never-smoker). Response rate (RR), time-to-progression (TTP) and overall survival (OS) were analyzed. Multivariate analysis was performed to investigate which approach yielded better prediction. RESULTS: RRs according to number of clinical predictors were 0: 3.4%, 1: 17.1%, 2: 29.4% and 3: 33.3% (p=0.002). Patients with gefitinib-sensitive EGFR mutation showed 61.9% RR compared with 12.1% in the remaining patients (p<0.001). RRs were higher in patients with the EGFR mutations regardless of the number of clinical predictors. In multivariate analysis, gefitinib-sensitive EGFR mutation showed higher odds ratio of response (9.6, 95% confidence interval [CI] 3.2-28.7) compared with number of clinical predictors (1.7, 95% CI 1.1-2.7). Hazard ratio (HR) of TTP was also better in gefitinib-sensitive EGFR mutation (0.24, 95% CI 0.12-0.47) than number of clinical predictors (0.83, 95% CI 0.69-0.99). Only gefitinib-sensitive EGFR mutation was associated with improved OS (HR 0.25, 95% CI 0.12-0.52). CONCLUSION: EGFR mutation should be analyzed whenever possible for effective prediction of objective benefit from gefitinib in NSCLC patients with one or more clinical predictors.